Seeking Alpha
Value, growth, long-term horizon, medium-term horizon
Profile| Send Message|
( followers)  

Do you consider yourself a value investor? We ran a screen with this perspective in mind.

We began by screening the healthcare sector for highly liquid stocks, with current ratios above 3.

We then screened for those that may be undervalued, by comparing price trends to changes in EPS estimates over the last month.

Based on the assumption that P/E is equal to a constant k, increases in EPS should be matched by increases in price. When they don't match up, a mispricing may have occurred.

We screened for stocks with faster growth in EPS estimates than price over the last month, which may indicate that these names are being undervalued.

For an interactive version of this chart, click on the image below. Analyst ratings sourced from Zacks Investment Research.

Tool provided by Kapitall (www.kapitall.com).

Do you think these stocks should be trading higher? Use this list as a starting point for your own analysis.

List sorted by increase in EPS estimate over the last month.

1. Abiomed Inc. (NASDAQ:ABMD): Engages in the research, development, and sale of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Market cap at $842.78M, most recent closing price at $21.32. Current ratio at 5.95. The EPS estimate for the company's current year increased from 0.24 to 0.28 over the last 30 days, an increase of 16.67%. This increase came during a time when the stock price changed by -12.32% (from 23.71 to 20.79 over the last 30 days).

2. SurModics Inc. (NASDAQ:SRDX): Provides drug delivery and surface modification technologies to the healthcare industry. Market cap at $321.33M, most recent closing price at $18.32. Current ratio at 16.6. The EPS estimate for the company's current year increased from 0.53 to 0.61 over the last 30 days, an increase of 15.09%. This increase came during a time when the stock price changed by 9.73% (from 16.85 to 18.49 over the last 30 days).

3. Syneron Medical Ltd. (NASDAQ:ELOS): Engages in the research, development, marketing, and sale of aesthetic medical products worldwide. Market cap at $355.52M, most recent closing price at $10.04. Current ratio at 3.05. The EPS estimate for the company's current year increased from 0.23 to 0.26 over the last 30 days, an increase of 13.04%. This increase came during a time when the stock price changed by -4.81% (from 10.61 to 10.1 over the last 30 days).

4. BioSpecifics Technologies Corp. (NASDAQ:BSTC): Involves in the development of an injectable collagenase for various indications. Market cap at $116.92M, most recent closing price at $18.47. Current ratio at 11.62. The EPS estimate for the company's current year increased from 0.29 to 0.33 over the last 30 days, an increase of 13.79%. This increase came during a time when the stock price changed by -3.01% (from 19.59 to 19 over the last 30 days).

5. Salix Pharmaceuticals Ltd. (NASDAQ:SLXP): Develops, and commercializes prescription drugs for the treatment of gastrointestinal disorders in the United States. Market cap at $2.65B, most recent closing price at $45.04. Current ratio at 4.66. The EPS estimate for the company's current year increased from 2.62 to 2.89 over the last 30 days, an increase of 10.31%. This increase came during a time when the stock price changed by -11.99% (from 52.06 to 45.82 over the last 30 days).

6. Cubist Pharmaceuticals Inc. (NASDAQ:CBST): Operates as a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. Market cap at $2.8B, most recent closing price at $43.80. Current ratio at 4.2. The EPS estimate for the company's current year increased from 1.67 to 1.84 over the last 30 days, an increase of 10.18%. This increase came during a time when the stock price changed by 6.37% (from 40.63 to 43.22 over the last 30 days).

7. Alkermes plc (NASDAQ:ALKS): Provides extended-release injectable and oral products for the treatment of prevalent and chronic diseases, such as central nervous system disorders, reward disorders, addiction, diabetes, and autoimmune disorders. Market cap at $2.38B, most recent closing price at $18.22. Current ratio at 4.95. The EPS estimate for the company's current year increased from 0.69 to 0.76 over the last 30 days, an increase of 10.14%. This increase came during a time when the stock price changed by -4.95% (from 18.78 to 17.85 over the last 30 days).

8. United Therapeutics Corporation (NASDAQ:UTHR): Engages in the development and commercialization of therapeutic products for patients with chronic and life-threatening diseases in the United States and Internationally. Market cap at $2.86B, most recent closing price at $55.26. Current ratio at 3.04. The EPS estimate for the company's current year increased from 4.65 to 5 over the last 30 days, an increase of 7.53%. This increase came during a time when the stock price changed by 5.44% (from 53.32 to 56.22 over the last 30 days).

*EPS data sourced from Yahoo! Finance, all other data sourced from Finviz.

Source: 8 Highly Liquid Healthcare Stocks Undervalued By EPS Trends